Free Trial
NASDAQ:MLTX

MoonLake Immunotherapeutics Q3 2024 Earnings Report

MoonLake Immunotherapeutics logo
$44.87 +1.37 (+3.15%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$44.60 -0.27 (-0.60%)
As of 07:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MoonLake Immunotherapeutics EPS Results

Actual EPS
-$0.56
Consensus EPS
-$0.44
Beat/Miss
Missed by -$0.12
One Year Ago EPS
-$0.18

MoonLake Immunotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MoonLake Immunotherapeutics Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

MoonLake Immunotherapeutics' Q1 2025 earnings is scheduled for Wednesday, August 6, 2025

Earnings Documents

MoonLake Immunotherapeutics Earnings Headlines

Fuel from trash? Texas startup turns waste into cash flow
Plastic waste isn't just an environmental issue - it's becoming a public health emergency. Microplastics have been found in human blood, breastmilk, and even placental tissue. And with 151,000 tons of plastic waste now stranded onshore due to export bans, landfills are overwhelmed and municipalities are scrambling for alternatives. One U.S. company may have found the answer.
See More MoonLake Immunotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MoonLake Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MoonLake Immunotherapeutics and other key companies, straight to your email.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

View MoonLake Immunotherapeutics Profile

More Earnings Resources from MarketBeat